Zhicheng Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhicheng Yao has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Changxiang Shi
Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China
46 shared publications - Chu-Xia Deng
Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China
46 shared publications - Chunfei Wang
Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China
46 shared publications - Hao Tian
Center for Brain Science The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
46 shared publications - Heng Sun
CRDA, Faculty of Health Sciences, University of Macau, Taipa, Macau
46 shared publications - Jianjie Li
Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China
46 shared publications
Latest Publications
- Open Access
- 11 May 2026
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Metabolic Dysfunction-associated Steatotic Liver Disease Diminishes the Efficacy of miR-125b-5p-engineered MSC Therapy for Hepatocellular Carcinoma via HK2 Upregulation: A Multimodal Theranostic Study
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, underscoring the need for effective therapies. Although miR-125b-5p shows therapeutic potential, its efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC and the underlying mechanisms remain unclear. In this study, we aimed to develop an MRI-trackable miR-125b-5p-engineered MSC platform for HCC therapy and to determine whether MASLD attenuates its antitumor efficacy through metabolic reprogramming.
- 11 May 2026
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessMetabolic Dysfunction-associated Steatotic Liver Disease Diminishes the Efficacy of miR-125b-5p-engineered MSC Therapy for Hepatocellular Carcinoma via HK2 Upregulation: A Multimodal Theranostic Study
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, underscoring the need for effective therapies. Although miR-125b-5p shows therapeutic potential, its efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC and the underlying mechanisms remain unclear. In this study, we aimed to develop an MRI-trackable miR-125b-5p-engineered MSC platform for HCC therapy and to determine whether MASLD attenuates its antitumor efficacy through metabolic reprogramming.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
All supplementary tables in one excel file
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
All supplementary tables in one excel file